PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism

Context: Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-Acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism. Objective: This work aimed to investigate the safety, tolerability, and efficacy of daily Tra...

Full description

Saved in:
Bibliographic Details
Main Authors: Aliya Khan, Lars Rejnmark, Mishaela R. Rubin, Peter Schwarz, Tamara Vokes, B.L. Clarke, Intekhab Ahmed, Lorenz C. Hofbauer, Claudio Marcocci, Uberto Pagotto, Andrea Palermo, Erik Fink Eriksen, Meryl Brod, Denka Markova, Alden Smith, Susanne Pihl, Sanchita Mourya, David Karpf, Aimee Shu
Format: Artigo
Language:English
Published: 2021
Online Access:https://doi.org/10.1210/clinem/dgab577
https://academic.oup.com/jcem/article-pdf/107/1/e372/41819574/dgab577.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1210/clinem/dgab577
https://academic.oup.com/jcem/article-pdf/107/1/e372/41819574/dgab577.pdf

Similar Items